Active Heart, Stroke & Blood Bones, Joints & Muscles

Finding a cure for aortic stenosis

In plain English

AI plain-English summary

Aortic stenosis—a progressive narrowing of the heart’s main valve—kills every patient who does not receive a replacement valve, yet no drug exists to slow or stop the disease. This matters because aortic stenosis is the most common heart valve disorder in the Western world. Current treatment is limited to surgical or catheter-based valve replacement, which carries risks and is followed by gradual deterioration of the new valve. No medical therapy can prevent, halt, or delay the underlying disease process. The research team will study tissue from explanted human valves and develop non-invasive molecular imaging to track disease progression in living patients. They will build a longitudinal cohort that repeatedly measures patients across the full course of their disease, using advanced imaging and biomarkers. Early proof-of-concept experimental medicine studies will identify the most promising molecular targets. If successful, this work could deliver the first drug treatment for aortic stenosis and for bioprosthetic valve degeneration—potentially delaying or avoiding the need for valve replacement surgery in thousands of patients each year.

View original technical description
Aortic stenosis is the commonest valvular heart disease in the western world. Although it is inevitably fatal if left untreated, there are currently no medical treatments that can prevent, halt, or delay the disease. Even after procedural valve intervention, problems remain including subsequent bioprosthetic valve degeneration. Our approach will be to apply experimental medicine approaches to define the pathogenesis and disease progression of aortic stenosis and bioprosthetic valve degeneration. We will achieve this in 3 complementary and synergistic ways: discovery human pathobiology, monitoring of in vivo disease progression, and preliminary proof-of-concept experimental medicine studies. We will exploit innovative approaches to study explanted human and bioprosthetic tissue and to develop non-invasive molecular imaging of the aortic valve. We will establish a longitudinal cohort platform study that will repeatedly phenotype patients with aortic stenosis across the life course of their disease using advanced multimodal imaging and disease biomarkers. We will undertake exploratory proof-of-concept experimental medicine studies to identify leading targets that can be subsequently progressed to phase 2 clinical interventional trials to achieve our goal of finding the first medical therapy to treat aortic stenosis and bioprosthetic valve degeneration.

View the original record at the funder ↗

Researchers

David Newby (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Early Valve Replacement guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients with Severe Aortic Stenosis
Mechanisms of Excess Risk in Aortic Stenosis (The MASTER Study)
Mechanisms of Excess Risk in Aortic STEnosis after Aortic Valve Replacement (MASTER)
Impact of early valve replacement on myocardial scar in asymptomatic Aortic Stenosis: an observational MRI study of randomised cohorts.
The Role of Valvular Fibrosis in Patients with Aortic Stenosis

Original classification

Programme Grant

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.